Analysts Set Expectations for BRNS Q1 Earnings

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) – HC Wainwright issued their Q1 2027 EPS estimates for shares of Barinthus Biotherapeutics in a research note issued on Tuesday, August 25th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.27) per share for the quarter. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($1.07) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02.

Separately, Weiss Ratings lowered shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Stock Up 9.3%

Shares of NASDAQ:BRNS opened at $0.66 on Wednesday. Barinthus Biotherapeutics has a 52-week low of $0.51 and a 52-week high of $1.83. The stock has a market cap of $26.92 million, a P/E ratio of -0.64 and a beta of -0.39. The business has a fifty day moving average of $0.62 and a two-hundred day moving average of $0.63.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several institutional investors have recently bought and sold shares of BRNS. Rangeley Capital LLC lifted its holdings in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after buying an additional 75,024 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. raised its stake in shares of Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares in the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.